Skip to main content
Caplight Logo









Kivu Biosciences

Kivu Biosciences

Private
San Mateo, CaliforniaHealthcare & Life Scienceshttps://kivubioscience.com/

Last Round

Series A

Oct 28, 2024

Total Funding Raised

$92M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Kivu Biosciences is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCsolid tumor oncologytargeted cancer therapybiotechclinical-stage biotechlinker-payload technologycancer drug developmentoncology therapeuticsdrug discoveryclinical trialsnext-gen oncologybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kivu Biosciences Comparables

Compare Kivu Biosciences with similar companies based on industry and business-model similarity.

Kivu Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Adcentrx Therapeutics
88%
Adcendo
81%
Duality Biotherapeutics Inc
77%

Kivu Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 28, 2024

Key People

Founding team and executive leadership

Mohit Trikha

President COO

Executive Team

Kivu Biosciences Investors

Notable investors and investment history

Kivu Biosciences investors
InvestorRounds
Brabantse Ontwikkelings MaatschappijSeries A
GimvSeries A
M VenturesSeries A
HealthCapSeries A
Novo HoldingsSeries A
BioGeneration VenturesSeries A
Red Tree Venture CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 31, 2026

    Open roles increased to 6, 3x the trailing average.

  • Apr 22, 2026

    Grew 20% QoQ, from 20 to 24 employees.

Kivu Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kivu Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kivu Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Mateo, California
Employee Range26
Year Founded2024
Last FundingOct 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?